A chemotherapy-free combination regimen with the novel BCL-2 inhibitor venetoclax (formerly ABT-199/GDC-0199) and the monoclonal anti-CD20 antibody rituximab induces durable responses in elderly patients with chronic lymphocytic leukaemia (CLL) who have failed at least two lines of standard treatment in a phase 1b study.
Relapsed and refractory multiple myeloma (MM) patients saw a 30 percent reduced risk of disease progression – gaining almost 5 progression-free months – on a regimen that included the novel immune therapy elotuzumab, according to the results of a global trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.